In this sense, Kodosaki et al. (28) claimed that combinations of biomarkers were considerably better than single biomarker predictions and specifically the combination of CSF [chitinase-3-like-1 + TNF-receptor-1 + CD27] and serum [osteopontin + MCP-1] presented an area under the curve of 0.97 for MS diagnosis. This evidence concerns the gene CCL2 and myeloid sarcoma.